Cargando…

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8(+) T Cell Responses

Cancer vaccination aims at inducing an adaptive immune response against tumor-derived antigens. In this study, we utilize recombinant human adenovirus serotype 5 (rAd5) and recombinant lymphocytic choriomeningitis virus (rLCMV)-based vectors expressing the melanocyte differentiation antigen gp100. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ring, Sandra S., Królik, Michał, Hartmann, Fabienne, Schmidt, Erika, Ali, Omar Hasan, Ludewig, Burkhard, Kochanek, Stefan, Flatz, Lukas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658660/ https://www.ncbi.nlm.nih.gov/pubmed/33209978 http://dx.doi.org/10.1016/j.omto.2020.10.001

Ejemplares similares

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
por: Fässler, Mirjam, et al.
Publicado: (2019)

Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack
por: Bonilla, Weldy V., et al.
Publicado: (2021)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination
por: Vasconcelos, José R., et al.
Publicado: (2012)

Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8(+ )T cell immunity
por: Bot, Adrian, et al.
Publicado: (2010)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment
por: Ring, Sandra S., et al.
Publicado: (2021)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Revival of the heterologous prime‐boost technique in COVID‐19: An outlook from the history of outbreaks
por: Siddiqui, Amna, et al.
Publicado: (2022)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

LFA-1 Mediates Cytotoxicity and Tissue Migration of Specific CD8(+) T Cells after Heterologous Prime-Boost Vaccination against Trypanosoma cruzi Infection
por: Ferreira, Camila Pontes, et al.
Publicado: (2017)

CD4 and CD8 T Cell Responses to the M. tuberculosis Ag85B-TB10.4 Promoted by Adjuvanted Subunit, Adenovector or Heterologous Prime Boost Vaccination
por: Elvang, Tara, et al.
Publicado: (2009)

Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8(+) T cells
por: Cupovic, Jovana, et al.
Publicado: (2021)

Hyperglycosylated gp120 mutants elicit improved CD4-binding site directed antibodies in a heterologous prime:boost regimen
por: Ahmed, FK, et al.
Publicado: (2012)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse
por: Guo, Qianqian, et al.
Publicado: (2020)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
por: Ramirez-Valdez, Ramiro A., et al.
Publicado: (2023)

Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques
por: Keelapang, Poonsook, et al.
Publicado: (2023)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines
por: Kittler, Julia M., et al.
Publicado: (2019)

Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect
por: Hofer, Tamara, et al.
Publicado: (2021)

Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains
por: Wang, Jiong, et al.
Publicado: (2021)

TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia)
por: Jayakumar, Asha, et al.
Publicado: (2011)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost
por: Apostólico, Juliana de Souza, et al.
Publicado: (2016)

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice
por: Aitken, Amelia S., et al.
Publicado: (2018)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_le0t5enajlr3tq7j09871c8rrg